News | August 12, 2024
Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Subscribe To Our Newsletter & Stay Updated
